The blasts react with antibodies to myeloperoxidase and antibodies to CD13, CD33, and CD34.
CD33 |
As the leader of the Cure Alzheimer’s Fund Alzheimer’s Genome Project, Dr. Tanzi has carried out multiple genome wide association studies of thousands of Alzheimer’s families leading to the identification of novel AD candidate genes, including CD33 and the first two rare mutations causing late-onset AD in the ADAM10 gene.